文献速递乳腺癌

ERBB2阳性转移性乳腺癌新型靶向药物的实践模式与结局

Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer.
PubMed 文献 · JAMA Oncol · 2021-09-16

该基于人群的回顾性队列研究纳入加拿大安大略省795例接受帕妥珠单抗和506例接受T-DM1治疗的ERBB2阳性转移性乳腺癌女性,描述真实世界实践模式与生存结局。结果显示帕妥珠单抗组中位OS为43个月,T-DM1组为15个月,均劣于关键临床试验;既往帕妥珠单抗暴露者T-DM1治疗后中位OS更短(12 vs 19个月)。

要点

  • 真实世界中帕妥珠单抗和T-DM1的生存结局劣于关键临床试验。
  • T-DM1队列中既往帕妥珠单抗暴露比例从2014年74.7%升至2017年18.0%。
  • 既往帕妥珠单抗暴露者T-DM1治疗后中位OS短于未暴露者(12 vs 19个月)。

核心结论

  • 真实世界实践中帕妥珠单抗和T-DM1治疗的生存结局似乎劣于关键临床试验结果。
  • 结局差异可能反映患者人群和既往治疗线数的不同。
  • 需要进一步研究帕妥珠单抗暴露后T-DM1的有效性。

研究设计与样本

  • 基于人群的回顾性队列研究,使用安大略癌症登记处链接电子治疗数据库。
  • 纳入2013年12月至2017年12月接受帕妥珠单抗一线治疗的795例IV期ERBB2阳性转移性乳腺癌女性。
  • 纳入2014年5月至2017年12月接受T-DM1治疗的506例患者,两个队列分别分析。

主要发现

  • 帕妥珠单抗队列中位(IQR)OS为43(16.2-不可评估)个月,中位治疗时间为14(6.0-26.2)个月。
  • T-DM1队列中位(IQR)OS为15(6.7-27.7)个月,中位治疗时间为4(1.4-9.0)个月。
  • T-DM1队列中既往帕妥珠单抗未暴露患者比例从2014年的68/91(74.7%)降至2017年的16/89(18.0%)(P < .001)。
  • 既往帕妥珠单抗治疗者中位OS短于未暴露者(12 vs 19个月;调整HR 0.70;95% CI 0.55-0.89;P = .004)。

临床怎么用

  • 真实世界数据提示靶向治疗顺序和患者选择可能影响生存结局,需结合既往治疗史评估T-DM1疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Clinical trials have shown that the addition of pertuzumab to trastuzumab-based chemotherapy for first-line treatment of ERBB2-positive metastatic breast cancer is associated with considerable improvement in overall survival (OS). In the second-line setting, trastuzumab emtansine (T-DM1) improves OS compared with capecitabine/lapatinib in patients previously treated with trastuzumab-based chemotherapy. However, there are few data describing long-term real-world outcomes with these agents. OBJECTIVE: To describe practice patterns and outcomes associated with pertuzumab and T-DM1 in routine clinical practice. DESIGN, SETTING, AND PARTICIPANTS: This population-based retrospective cohort study used the Ontario Cancer Registry linked to electronic treatment databases to identify all patients treated with pertuzumab and T-DM1 following reimbursement approval in Ontario, Canada, which has a single-payer public health system. Participants included women with stage IV ERBB2-positive metastatic breast cancer receiving treatment with pertuzumab for first-line metastatic indication from December 2013 through December 2017, and those treated with T-DM1 from May 2014 through December 2017. Pertuzumab and T-DM1 cohorts were analyzed separately. Data were analyzed December 2019 to December 2020. EXPOSURES: Treatment with pertuzumab or T-DM1. MAIN OUTCOMES AND MEASURES: The primary outcome was OS, determined using the Kaplan-Meier method. Factors associated with OS were identified using a Cox proportional hazard model. RESULTS: The median (interquartile range [IQR]) age of the 795 women who received pertuzumab and 506 women who received T-DM1 was 57 (49-67) and 56 (48-66) years, respectively. Among the cohort of patients who received pertuzumab, the median (IQR) OS and time on treatment was 43 (16.2-unavailable) and 14 (6.0-26.2) months, respectively. In the T-DM1 cohort, the proportion of pertuzumab-naive patients decreased over time from 68 of 91 [74.7%] in 2014 to 16 of 89 [18.0%] in 2017 (P < .001). The median (IQR) OS and time on treatment was 15 (6.7-27.7) and 4 (1.4-9.0) months, respectively. Median OS was shorter for patients with prior pertuzumab treatment than in the pertuzumab-naive subgroup (12 vs 19 months; adjusted hazard ratio, 0.70; 95% CI, 0.55-0.89; P = .004). CONCLUSIONS AND RELEVANCE: In this population-based cohort study, the survival of patients treated with pertuzumab and T-DM1 in routine practice appeared inferior to results from pivotal clinical trials. Differences in outcome likely reflect differences in patient population and previous lines of therapy in routine practice. Further work is needed to understand the effectiveness of T-DM1 after pertuzumab exposure.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Ethier JL, Desautels D, Robinson A, et al. Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer. JAMA Oncol. 2021. PMID: 34236387. doi:10.1001/jamaoncol.2021.2140

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。